Line M. Myklebust
- Oncology top 5%
- Peptidase Inhibition and Analysis 10
- Geriatrics and Gerontology top 5%
- Molecular Biology top 10%
- Protein Kinase Regulation and GTPase Signaling 4
- Melanoma and MAPK Pathways 3
- Signaling Pathways in Disease 3
- Ubiquitin and proteasome pathways 3
-
- Protease and Inhibitor Mechanisms 5
-
- Ferrocene Chemistry and Applications 2
-
- Metabolism and Genetic Disorders 2
- Co-authors
- Thomas ArnesenRasmus ReeAdrian DrazicSvein I. StøveJan Erik VarhaugHåvard FoynKris GevaertPetra Van Damme
- Partner nations
- NorwayUnited StatesBelgium
In The Last Decade
Line M. Myklebust
19 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Oncology 543
- Geriatrics and Gerontology 65
- Molecular Biology 934
- Cancer Research 151
- Virology 21
Countries citing papers authored by Line M. Myklebust
This map shows the geographic impact of Line M. Myklebust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Line M. Myklebust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Line M. Myklebust more than expected).
Fields of papers citing papers by Line M. Myklebust
This network shows the impact of papers produced by Line M. Myklebust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Line M. Myklebust. The network helps show where Line M. Myklebust may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Line M. Myklebust, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2020 | 2 | |
| 3 | 2018 | 60 | |
| 4 | 2018 | 24 | |
| 5 | 2018 | 23 | |
| 6 | 2018 | 6 | |
| 7 | 2017 | 13 | |
| 8 | 2016 | 48 | |
| 9 | The world of protein acetylationbreakdown → | 2016 | 598 |
| 10 | 2015 | 105 | |
| 11 | 2015 | 41 | |
| 12 | 2014 | 63 | |
| 13 | 2014 | 88 | |
| 14 | 2014 | 3 | |
| 15 | 2011 | 32 | |
| 16 | 2011 | 11 | |
| 17 | 2010 | 1 | |
| 18 | 2007 | 56 | |
| 19 | 2006 | 7 |
About Line M. Myklebust
Line M. Myklebust is a scholar working on Oncology, Cancer Research and Clinical Biochemistry, having authored 19 papers that have together received 1.2k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (10 papers), Protease and Inhibitor Mechanisms (5 papers), Protein Kinase Regulation and GTPase Signaling (4 papers), Melanoma and MAPK Pathways (3 papers), Signaling Pathways in Disease (3 papers), Ubiquitin and proteasome pathways (3 papers), Ferrocene Chemistry and Applications (2 papers) and Metabolism and Genetic Disorders (2 papers). The work is most often cited by research in Oncology (543 citations), Geriatrics and Gerontology (65 citations) and Molecular Biology (934 citations). Line M. Myklebust has collaborated with scholars based in Norway, United States and Belgium. Frequent co-authors include Thomas Arnesen, Rasmus Ree, Adrian Drazic, Svein I. Støve, Jan Erik Varhaug, Håvard Foyn, Kris Gevaert, Petra Van Damme, Johan R. Lillehaug and Frédéric Pendino.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.